NCT05875584Completed
Exploratory Study of a Novel Based rbcDNA Liquid Biopsy Technique for Colorectal Cancer Early Detection
Source: ClinicalTrials.gov · Last updated 27 Aug 2024
Brief summary (registry, in English)
Exploration of a novel rbcDNA liquid biopsy technique for early detection of colorectal cancer is a promising development in the field of disease diagnosis and screening. This technique has the potential to establish an efficient and sensitive system for the early detection of colorectal cancer, which can provide a new perspective for individual health monitoring.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 598 (actual)
- First submitted
- 4 May 2023
- Start date
- 18 May 2023
- Primary completion date
- 28 Dec 2023
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Diseases
- Colorectal cancer
- NCT number
- NCT05875584
What you commit to
- Study type: Observational
- Participants enrolled: 598
- From 18 May 2023 to the primary completion date, 28 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with colorectal cancer who have received prior treatment.
- Prior history of colonoscopy within the past 5 years and removal of lesions
Other illness
- FAP (familial adenomatous polyposis), Crohn's disease, ulcerative colitis
- Participants taking anticoagulants such as aspirin or warfarin, or those with coagulation disorders.
- Presence of major infectious diseases (e.g. HIV, etc.)
Other
- Pregnancy or intestinal infarction people
- Unable to provide informed consent
- Participants in other clinical trials or who have participated in other clinical trials within 60 days.
- Unable to provide stool sample and follow-up visits.
Who the study is looking for
- Age:40-74Years
- Sex:All
- Willing to provide written consent
- Plan to undergo colorectaloscopy or surgical treatment and be able to provide a complete medical history and cooperate with blood sampling and follow-up visits，other operation.
- For advanced adenomas (AA) group:
- Adenomatous polyps with ≥25% villous component, high-grade dysplasia (HGD), or a diameter ≥10 mm were considered AA. Sessile serrated lesions with diameters ≥10 mm.
- treatment-naive
- No other comorbid tumors
- For CRC group:
- Confirmed CRC patients
- treatment-naive
- No other comorbid tumors
Age in the registry: 40 years to 74 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Second Affiliated Hospital, School of Medicine, Zhejiang University Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.